KLRK1 and glioblastoma: ,22,23 Together with the fact that CD3ζ downstream signaling alone was sufficient to direct anti-tumor activity in macrophages,24 we therefore identified the NKG2D CAR suitable for a cross-comparison of CAR immune effector cells against glioblastoma.